Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: A validation study

Annals of Family Medicine

Volumn 9, Issue 5, 2011, Pages 431-438

  Buitrago, Francisco ^a   Calvo Hueros, Juan Ignacio ^a   Cañón Barroso, Lourdes ^a   Pozuelos Estrada, Gerónimo ^a   Molina Martínez, Luis ^a   Espigares Arroyo, Manuel ^a   Galán González, Juan Antonio ^a   Lillo Bravo, Francisco J ^a  

^a Centro de Salud Universitario 'La Paz'   (Spain)

Author keywords

Antihypertensive agents; Cardiovascular risk functions; Coronary disease; Framingham function; Hypolipidemic agents; REGICOR risk chart

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; FEMALE; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MALE; METHODOLOGY; MIDDLE AGED; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; SPAIN; STATISTICAL MODEL; VALIDATION STUDY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SPAIN;

EID: 80052695262     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1287     Document Type: Article

References (39)

1. Sans S, Kestekoot H, Kromhout D. The burden of cardiovascular disease mortality in Europe. Task Force on the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18(8):1231-1248.
2. World Health Organization. Fact sheet no. 317. January 2011. http://www.who.int/mediacentre/factsheets/fs317/en/.
3. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contributions of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet. 1999;353(9164):1545-1557.
4. Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338:b375.
5. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009;339:b2584.
6. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörala K. Task Force Report. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of the joint European Societies on coronary prevention. Eur Heart J. 1998;19(10):1434-1503.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
8. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
9. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk prof le. A statement for health professionals. Circulation. 1991;83(1):356-362.
10. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-1847.
11. Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart. 2000;84(3):238-244.
12. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000;21(5):365-370.
13. Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary risk function to southern Europe Mediterranean areas. J Epidemiol Community Health. 2003;57(8):634-638.
14. Chamnan P, Simmons RK, Hori H, et al. A simple risk score using routine data for predicting cardiovascular disease in primary care. Br J Gen Pract. 2010;60(577):e327-e334.
15. Hense HW, Schulte H, Löwel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003;24(10):937-945.
16. Thomsen T F, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol. 2002;31(4):817-822.
17. Empana JP, Ducimetière P, Arveiler D, et al; PRIME Study Group. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24(21):1903-1911.
18. Marrugat J, Solanas P, D'Agostino R, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56(3):253-261.
19. Marrugat J, Subirana I, Comín E, et al; VERIFICA Investigators. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health. 2007;61(1):40-47.
20. Baena Díez JM, del Val Garcia JL, Héctor Salas Gaetgens L, et al. Comparison of the SCORE and REGICOR models for calculating cardiovascular risk in cardiovascular disease-free individuals at a healthcare center in Barcelona, Spain. Rev Esp Salud Publica. 2005; 79(4):453-464.
21. Cañón Barroso L, Díaz Herrera N, Cruces Muro E, Nieto Hernández T, Garrote Florencio T, Buitrago F. Predictive capacity, comparison and clinic consequences of the Framingham-Wilson and REGICOR tables in persons for whom care has been provided at a health care center, Badajoz, Spain. Rev Esp Salud Publica. 2007;81(4):353-364.
22. Liew SM, Glasziou P. QRISK validation and evaluation. QRISK may be less useful. BMJ. 2009;339:b3485.
23. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56 (11):1129-1135.
24. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24(17): 1601-1610.
25. Brotons C, Royo-Bordonada MA, Alvárez-Sala L, et al. Comité Espa-ñol Interdisciplinario para la Prevención Cardiovascular. Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention. Rev Esp Salud Publica. 2004;78(4):435-438.
26. Ramos R, Solanas P, Cordón F, et al. Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions. Med Clin (Barc). 2003;121(14): 521-526.
27. Maiques Galán A, Antón García F, Franch Taix M, Albert Ros X, Aleixandre Martí E, Collado Gil A. Cardiovascular risk of SCORE compared to Framingham. Consequences of the change proposed by the European Societies. Med Clin (Barc). 2004;123(18):681-685.
28. Fornasini M, Brotons C, Sellarès J, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Fam Pract. 2006;23(1):28-33.
29. Cristóbal J, Lago F, de la Fuente J, González-Juanatey JR, Vázquez-Bellés P, Vila M. Comparison of coronary risk estimates derived using the Framingham and REGICOR equations. Rev Esp Cardiol. 2005;58(8):910-915.
30. Buitrago F, Cañón-Barroso L, Díaz-Herrera N, Cruces-Muro E, Esco-bar-Fernández M, Serrano-Arias JM. Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment. Rev Esp Cardiol. 2007;60(2):139-147.
31. Baena-Díez JM, Grau M, Sánchez-Pérez R, Altes-Vaques E, Salas-Gaetjens LH, Hernández-Ibáñez MR. The REGICOR-calibrated function provides a better classif cation of high-risk patients on statin treatment in the Spanish population than the Framingham or SCORE classif cations. Rev Esp Cardiol. 2009;62(10):1134-1140.
32. Mainous AG III, Everett CJ, Player MS, King DE, Diaz VA. Importance of a patient's personal health history on assessments of future risk of coronary heart disease. J Am Board Fam Med. 2008;21(5):408-413.
33. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136-148.
34. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ. 2010;340:c2442. 10.1136/bmj.c2442.
35. Gérvas J, Starfeld B, Heath I. Is clinical prevention better than cure? Lancet. 2008;372(9654):1997-1999.
36. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med. 2006;144(3):201-209.
37. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart. 2008;94(1):34-39.
38. Mayor S. Doctors no longer have to use Framingham equation to assess heart disease risk, NICE says. BMJ. 2010;340:c1774.
39. Goodyear-Smith F, Arroll B, Chan L, Jackson R, Wells S, Kenealy T. Patients prefer pictures to numbers to express cardiovascular ben-ef t from treatment. Ann Fam Med. 2008;6(3):213-217.